Fallopian Tube Cancer - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 432 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fallopian Tube Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Fallopian Tube Cancer - Pipeline Review, H1 2015’, provides an overview of the Fallopian Tube Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Fallopian Tube Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Fallopian Tube Cancer - Overview 11
Pipeline Products for Fallopian Tube Cancer - Comparative Analysis 12
Fallopian Tube Cancer - Therapeutics under Development by Companies 13
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 18
Fallopian Tube Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Fallopian Tube Cancer - Products under Development by Companies 22
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 27
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Acceleron Pharma, Inc. 29
Adaptimmune Limited 30
Amgen Inc. 31
Array BioPharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
Bayer AG 35
BioMarin Pharmaceutical Inc. 36
Bionomics Limited 37
Boehringer Ingelheim GmbH 38
Celldex Therapeutics, Inc. 39
Celsion Corporation 40
Cerulean Pharma, Inc. 41
Clovis Oncology, Inc. 42
Corcept Therapeutics Incorporated 43
CTI BioPharma Corp. 44
Curis, Inc. 45
Eli Lilly and Company 46
Exelixis, Inc. 47
F. Hoffmann-La Roche Ltd. 48
Galena Biopharma, Inc. 49
Genentech, Inc. 50
GlaxoSmithKline plc 51
Glycotope GmbH 52
Gradalis Inc. 53
ImmunoGen, Inc. 54
Immunotope, Inc. 55
Immunovaccine, Inc. 56
Johnson & Johnson 57
Karyopharm Therapeutics, Inc. 58
Lee's Pharmaceutical Holdings Limited 59
MabVax Therapeutics Holdings, Inc. 60
MedImmune, LLC 61
Merck & Co., Inc. 62
Merrimack Pharmaceuticals, Inc. 63
Millennium Pharmaceuticals, Inc. 64
NeoStem, Inc. 65
Novartis AG 66
Oasmia Pharmaceutical AB 67
OBI Pharma, Inc. 68
Oncolytics Biotech Inc. 69
OncoMed Pharmaceuticals, Inc. 70
Onxeo SA 71
Oxford BioMedica plc 72
OXiGENE, Inc. 73
Pharma Mar, S.A. 74
Pharmacyclics, Inc. 75
PsiOxus Therapeutics, Ltd. 76
Recepta Biopharma S.A. 77
Sanofi Pasteur SA 78
Sotio a.s. 79
Synta Pharmaceuticals Corp. 80
TapImmune Inc. 81
Tesaro, Inc. 82
TetraLogic Pharmaceuticals 83
TRACON Pharmaceuticals, Inc. 84
VentiRx Pharmaceuticals, Inc. 85
Fallopian Tube Cancer - Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Target 87
Assessment by Mechanism of Action 91
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 98
abexinostat hydrochloride - Drug Profile 98
abiraterone acetate - Drug Profile 100
ABT-767 - Drug Profile 103
alisertib - Drug Profile 104
anetumab ravtansine - Drug Profile 108
AZD-1775 - Drug Profile 110
AZD-2014 - Drug Profile 112
AZD-5363 - Drug Profile 114
belinostat - Drug Profile 116
bevacizumab - Drug Profile 119
binimetinib - Drug Profile 124
birinapant - Drug Profile 128
BNC-105P - Drug Profile 131
cabozantinib s-malate - Drug Profile 133
Cancer Stem Cell Therapy - Drug Profile 136
CDX-1401 - Drug Profile 137
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 139
Cell Therapy to Target WT1 for Cancer - Drug Profile 141
CRLX-101 - Drug Profile 142
CUDC-427 - Drug Profile 144
dalantercept - Drug Profile 145
DCVAC/OvCa - Drug Profile 147
demcizumab - Drug Profile 148
Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile 152
DMUC-4064A - Drug Profile 153
DPX-Survivac - Drug Profile 154
EGEN-001 - Drug Profile 157
elesclomol - Drug Profile 159
enadenotucirev - Drug Profile 161
erismodegib - Drug Profile 163
fosbretabulin tromethamine - Drug Profile 166
GALE-301 - Drug Profile 170
ganetespib - Drug Profile 172
gimatecan - Drug Profile 176
guadecitabine - Drug Profile 178
IMGN-853 - Drug Profile 181
IMT-1012 - Drug Profile 182
ipafricept - Drug Profile 183
LCL-161 - Drug Profile 185
lifastuzumab vedotin - Drug Profile 187
LY-2606368 - Drug Profile 189
mifepristone - Drug Profile 190
MK-2206 - Drug Profile 193
motolimod - Drug Profile 196
nintedanib - Drug Profile 198
niraparib - Drug Profile 202
NSC-748933 - Drug Profile 204
OBI-822/821 - Drug Profile 205
olaratumab - Drug Profile 207
paclitaxel - Drug Profile 209
paclitaxel poliglumex - Drug Profile 211
PankoMab-GEX - Drug Profile 215
pazopanib hydrochloride - Drug Profile 216
pelareorep - Drug Profile 221
ralimetinib mesylate - Drug Profile 226
ramucirumab - Drug Profile 227
RebmAb-100 - Drug Profile 232
regorafenib - Drug Profile 234
rucaparib phosphate - Drug Profile 237
selinexor - Drug Profile 240
seribantumab - Drug Profile 244
SG-2000 - Drug Profile 247
talazoparib - Drug Profile 249
TPIV-200 - Drug Profile 252
trabectedin - Drug Profile 254
TRC-105 - Drug Profile 258
trebananib - Drug Profile 260
TroVax - Drug Profile 263
Vaccine for cancer - Drug Profile 266
Vaccine for Oncology - Drug Profile 268
varlilumab - Drug Profile 269
vCP-2292 - Drug Profile 271
X-82 - Drug Profile 273
Fallopian Tube Cancer - Recent Pipeline Updates 275
Fallopian Tube Cancer - Dormant Projects 417
Fallopian Tube Cancer - Discontinued Products 419
Fallopian Tube Cancer - Product Development Milestones 420
Featured News & Press Releases 420
Appendix 426
Methodology 426
Coverage 426
Secondary Research 426
Primary Research 426
Expert Panel Validation 426
Contact Us 426
Disclaimer 427

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H1 2015 16
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Fallopian Tube Cancer - Pipeline by AbbVie Inc., H1 2015 33
Fallopian Tube Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 34
Fallopian Tube Cancer - Pipeline by Adaptimmune Limited, H1 2015 35
Fallopian Tube Cancer - Pipeline by Amgen Inc., H1 2015 36
Fallopian Tube Cancer - Pipeline by Array BioPharma Inc., H1 2015 37
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 38
Fallopian Tube Cancer - Pipeline by AstraZeneca PLC, H1 2015 39
Fallopian Tube Cancer - Pipeline by Bayer AG, H1 2015 40
Fallopian Tube Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 41
Fallopian Tube Cancer - Pipeline by Bionomics Limited, H1 2015 42
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 43
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 44
Fallopian Tube Cancer - Pipeline by Celsion Corporation, H1 2015 45
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 46
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 47
Fallopian Tube Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 48
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H1 2015 49
Fallopian Tube Cancer - Pipeline by Curis, Inc., H1 2015 50
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H1 2015 51
Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H1 2015 52
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53
Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 54
Fallopian Tube Cancer - Pipeline by Genentech, Inc., H1 2015 55
Fallopian Tube Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 56
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H1 2015 57
Fallopian Tube Cancer - Pipeline by Gradalis Inc., H1 2015 58
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H1 2015 59
Fallopian Tube Cancer - Pipeline by Immunotope, Inc., H1 2015 60
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H1 2015 61
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H1 2015 62
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 63
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 64
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 65
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H1 2015 66
Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H1 2015 67
Fallopian Tube Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 68
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 69
Fallopian Tube Cancer - Pipeline by NeoStem, Inc., H1 2015 70
Fallopian Tube Cancer - Pipeline by Novartis AG, H1 2015 71
Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 72
Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H1 2015 73
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 74
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 75
Fallopian Tube Cancer - Pipeline by Onxeo SA, H1 2015 76
Fallopian Tube Cancer - Pipeline by Oxford BioMedica plc, H1 2015 77
Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H1 2015 78
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H1 2015 79
Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 80
Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 81
Fallopian Tube Cancer - Pipeline by Recepta Biopharma S.A., H1 2015 82
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 83
Fallopian Tube Cancer - Pipeline by Sotio a.s., H1 2015 84
Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 85
Fallopian Tube Cancer - Pipeline by TapImmune Inc., H1 2015 86
Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H1 2015 87
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 88
Fallopian Tube Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 89
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 90
Assessment by Monotherapy Products, H1 2015 91
Number of Products by Stage and Target, H1 2015 93
Number of Products by Stage and Mechanism of Action, H1 2015 97
Number of Products by Stage and Route of Administration, H1 2015 100
Number of Products by Stage and Molecule Type, H1 2015 102
Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H1 2015 280
Fallopian Tube Cancer - Dormant Projects, H1 2015 422
Fallopian Tube Cancer - Dormant Projects (Contd..1), H1 2015 423
Fallopian Tube Cancer - Discontinued Products, H1 2015 424